Biopharma deals in review

Review of an extraordinary 2021 and expectations for the future.

While the biotech investment boom has lost some of its sizzle in recent months, 2021 was another extraordinary year for biopharma licensing, collaborations and joint ventures.

This year’s Deals Report digs into these and other emerging market trends, with detailed analysis of the key deals and an eye toward the implications for 2022.

Key themes included:

  • A maturation of deals toward co-development and co-commercialization, with partnerships enabling smaller biotechs to stand up their own commercialization efforts by leaning on larger pharmas.
  • The increasingly global nature of deal-making, driven in part by an explosion of innovation within Mainland China-based biotechs.
  • Continued energy around oncology therapeutics, though no longer led by immuno-oncology candidates, which made up only a third of overall oncology deals.
  • Pharmas seeking footholds within the enabling technologies underpinning next-generation treatments, such as RNA technologies and or cell and gene therapeutics.